Itron Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Itron in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Itron stock.
View analyst ratings for Itron or view top-rated stocks.

Wall Street analysts have given Itron a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Itron wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Itron is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Itron.

Itron, Inc. (NASDAQ:ITRI) released its quarterly earnings results on Thursday, August, 5th. The scientific and technical instruments company reported $0.28 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.48 by $0.20. The scientific and technical instruments company earned $489.41 million during the quarter, compared to analyst estimates of $531.53 million. Itron had a positive trailing twelve-month return on equity of 8.11% and a negative net margin of 2.58%. Itron's quarterly revenue was down 4.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.03 earnings per share.
View Itron's earnings history.

Itron's stock was trading at $66.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ITRI stock has increased by 7.7% and is now trading at $71.84.
View which stocks have been most impacted by COVID-19.

Itron issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of $1.000-$1.500 for the period, compared to the Thomson Reuters consensus estimate of $2.420. The company issued revenue guidance of $2.05 billion-$2.15 billion, compared to the consensus revenue estimate of $2.26 billion.

9 brokers have issued 12 month price targets for Itron's stock. Their forecasts range from $56.00 to $140.00. On average, they expect Itron's stock price to reach $107.13 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts' price targets for Itron or view top-rated stocks among Wall Street analysts.

3 employees have rated Itron CEO Tom Deitrich on Glassdoor.com. Tom Deitrich has an approval rating of 100% among Itron's employees. This puts Tom Deitrich in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Itron include Cognex (CGNX), Coherent (COHR), National Instruments (NATI), Badger Meter (BMI), OSI Systems (OSIS), Mesa Laboratories (MLAB), FARO Technologies (FARO), Vishay Precision Group (VPG) and Daktronics (DAKT).
View all of ITRI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Itron investors own include NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Applied Materials (AMAT), QUALCOMM (QCOM), Xilinx (XLNX), Intel (INTC), AT&T (T) and Tesla (TSLA).

Itron trades on the NASDAQ under the ticker symbol "ITRI."

Itron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Impax Asset Management Group plc (5.79%), Victory Capital Management Inc. (2.08%), PGGM Investments (1.72%), Guinness Asset Management LTD (0.53%), Peregrine Capital Management LLC (0.38%) and Rhumbline Advisers (0.29%). Company insiders that own Itron stock include Donald L Reeves III, Joan S Hooper, John F Marcolini, Lynda L Ziegler, Michel Cadieux, Philip Mezey, Sarah E Hlavinka, Sharelynn Faye Moore, Thomas Deitrich and Thomas S Glanville.
View institutional ownership trends for Itron.

ITRI stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Zurcher Kantonalbank Zurich Cantonalbank , Intrust Bank NA, Guinness Atkinson Asset Management Inc, and Arizona State Retirement System. Company insiders that have sold Itron company stock in the last year include Donald L Reeves III, Joan S Hooper, John F Marcolini, Lynda L Ziegler, Michel Cadieux, Sarah E Hlavinka, Thomas Deitrich, and Thomas S Glanville.
View insider buying and selling activity for Itron or view top insider-selling stocks.

ITRI stock was acquired by a variety of institutional investors in the last quarter, including Impax Asset Management Group plc, Peregrine Capital Management LLC, PGGM Investments, Victory Capital Management Inc., Guinness Asset Management LTD, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Alliancebernstein L.P., and Green Alpha Advisors LLC.
View insider buying and selling activity for Itron or or view top insider-buying stocks.

Shares of ITRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITRI stock can currently be purchased for approximately $71.84.

Itron has a market capitalization of $3.24 billion and generates $2.17 billion in revenue each year. The scientific and technical instruments company earns $-57,960,000.00 in net income (profit) each year or $1.85 on an earnings per share basis.

Itron employs 6,749 workers across the globe.

The official website for Itron is www.itron.com.

Itron is headquartered at 2111 N MOLTER ROAD, LIBERTY LAKE WA, 99019.

Itron's mailing address is 2111 N MOLTER ROAD, LIBERTY LAKE WA, 99019. The scientific and technical instruments company can be reached via phone at (509) 924-9900 or via email at [email protected]